James Wallace to Survival Rate
This is a "connection" page, showing publications James Wallace has written about Survival Rate.
Connection Strength
0.021
-
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Sep; 12(3):218-22.
Score: 0.021